Top

Published in:

01-04-2014 | Research Article

A pooled analysis of the ERCC2 Asp312Asn polymorphism and esophageal cancer susceptibility

Authors: Fang Wen, Zhiyong Zhao, Chuan Liu, Qinghua Yin, Jie Weng, Yajie Wang, Yuchen Ma

Published in: Tumor Biology | Issue 4/2014

Abstract

Published data regarding the association between the excision repair cross-complimentary group 2 (ERCC2) Asp312Asn polymorphisms and esophageal cancer susceptibility remained controversial. This meta-analysis of literatures was performed to assess the strength of association between the ERCC2 and esophageal cancer susceptibility using random effects model. We systematically searched PubMed, Embase and Web of Science with a time limit of September 15, 2013. Summary odds ratios (ORs) with 95 % confidence intervals (CIs) were used to assess the strength of association between the ERCC2 Asp312Asn polymorphism and esophageal cancer susceptibility using random effects model. A total of seven case–control studies including 1,831 cases and 2,728 controls were included for analysis. Overall, a significant association was found between ERCC2 Asp312Asn polymorphism and esophageal cancer susceptibility for GA vs. GG (OR = 1.20, 95 % CI = 1.03–1.40) and for the dominant model GA/AA vs. GG (OR = 1.18, 95 % CI = 1.03–1.35). However, the ERCC2 Asp312Asn polymorphism was a protective factor for AA vs. GA/GG (OR = 0.63, 95 % CI = 1.15–2.65) in esophageal squamous cell carcinoma. Our meta-analysis suggested that the ERCC2 Asp312Asn polymorphism might be associated with increased risk of esophageal adenocarcinoma and a protective factor for esophageal squamous cell carcinoma.

Yang SJ, Yokoyama A, Yokoyama T, Huang YC, Wu SY, Shao Y, et al. Relationship between genetic polymorphisms of ALDH2 and ADH1B and esophageal cancer risk: a meta-analysis. World J Gastroenterol. 2010;16:4210–20.PubMedCentralPubMedCrossRef

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.PubMedCrossRef

Jemal A, Center MM, Desantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19:1893–907.PubMedCrossRef

Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825–31.PubMedCrossRef

Mayne ST, Risch HA, Dubrow R, Chow WH, Gammon MD, Vaughan TL, et al. Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev. 2001;10:1055–62.PubMed

Wu IC, Lu CY, Kuo FC, Tsai SM, Lee KW, Kuo WR, et al. Interaction between cigarette, alcohol and betel nut use on esophageal cancer risk in Taiwan. Eur J Clin Invest. 2006;36:236–41.PubMedCrossRef

Kamangar F, Chow WH, Abnet CC, Dawsey SM. Environmental causes of esophageal cancer. Gastroenterol Clin North Am. 2009;38:27–57.PubMedCentralPubMedCrossRef

Ishibe N, Kelsey KT. Genetic susceptibility to environmental and occupational cancers. Cancer Causes Control. 1997;8:504–13.PubMedCrossRef

Duell EJ, Wiencke JK, Cheng TJ, Varkonyi A, Zuo ZF, Ashok TD, et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis. 2000;21:965–71.PubMedCrossRef

10.

Benhamou S, Sarasin A. ERCC2/XPD gene polymorphisms and lung cancer: a HuGE review. Am J Epidemiol. 2005;161:1–14.PubMedCrossRef

11.

Wang F, Chang D, Hu FL, Sui H, Han B, Li DD, et al. DNA repair gene XPD polymorphisms and cancer risk: a meta-analysis based on 56 case–control studies. Cancer Epidemiol Biomarkers Prev. 2008;17:507–17.PubMedCrossRef

12.

Neumann AS, Sturgis EM, Wei Q. Nucleotide excision repair as a marker for susceptibility to tobacco-related cancers: a review of molecular epidemiological studies. Mol Carcinog. 2005;42:65–92.PubMedCrossRef

13.

Arbault S, Sojic N, Bruce D, Amatore C, Sarasin A, Vuillaume M. Oxidative stress in cancer prone xeroderma pigmentosum fibroblasts. real-time and single cell monitoring of superoxide and nitric oxide production with microelectrodes. Carcinogenesis. 2004;25:509–15.PubMedCrossRef

14.

Shen MR, Jones IM, Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res. 1998;58:604–8.PubMed

15.

Chen DQ, Yao DX, Zhao HY, Yang SJ. DNA repair gene ERCC1 and XPD polymorphisms predict glioma susceptibility and prognosis. Asian Pac J Cancer Prev. 2012;13:2791–4.PubMedCrossRef

16.

Guo LY, Jin XP, Niu W, Li XF, Liu BH, Wang YL. Association of XPD and XRCC1 genetic polymorphisms with hepatocellular carcinoma risk. Asian Pac J Cancer Prev. 2012;13:4423–6.PubMedCrossRef

17.

Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5.PubMedCrossRef

18.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRef

19.

Ades AE, Lu G, Higgins JP. The interpretation of random-effects meta-analysis in decision models. Med Decis Making. 2005;25:646–54.PubMedCrossRef

20.

Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed

21.

Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29.CrossRef

22.

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.PubMedCrossRef

23.

Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.PubMedCrossRef

24.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 1997;315:629–34.CrossRef

25.

Xing DY, Qi J, Tan W, Miao XP, Liang G, Yu CY, et al. Association of genetic polymorphisms in the DNA repair gene XPD with risk of lung and esophageal cancer in a Chinese population in Beijing. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2003;20:35–8.PubMed

26.

Huang CG, Liu T, Lv GD, Liu Q, Feng JG, Lu XM. Analysis of XPD genetic polymorphisms of esophageal squamous cell carcinoma in a population of Yili Prefecture, in Xinjiang. China Mol Biol Rep. 2012;39:709–14.CrossRef

27.

Crane SJ, Richard Locke III G, Harmsen WS, Diehl NN, Zinsmeister AR, Joseph Melton III L, et al. The changing incidence of oesophageal and gastric adenocarcinoma by anatomic sub-site. Aliment Pharmacol Ther. 2007;25:447–53.PubMedCrossRef

28.

Tse D, Zhai R, Zhou W, Heist RS, Asomaning K, Su L, et al. Polymorphisms of the NER pathway genes, ERCC1 and XPD are associated with esophageal adenocarcinoma risk. Cancer Causes Control. 2008;19:1077–83.PubMedCentralPubMedCrossRef

29.

Liu G, Zhou W, Yeap BY, Su L, Wain JC, Poneros JM, et al. XRCC1 and XPD polymorphisms and esophageal adenocarcinoma risk. Carcinogenesis. 2007;28:1254–8.PubMedCrossRef

30.

Ye W, Kumar R, Bacova G, Lagergren J, Hemminki K, Nyrén O. The XPD 751Gln allele is associated with an increased risk for esophageal adenocarcinoma: a population-based case–control study in Sweden. Carcinogenesis. 2006;27:1835–41.PubMedCrossRef

31.

Yu HP, Wang XL, Sun X, Su YH, Wang YJ, Lu B, et al. Polymorphisms in the DNA repair gene XPD and susceptibility to esophageal squamous cell carcinoma. Cancer Genet Cytogenet. 2004;154:10–5.PubMedCrossRef

32.

Xing D, Qi J, Miao X, Lu W, Tan W, Lin D. Polymorphisms of DNA repair genes XRCC1 and XPD and their associations with risk of esophageal squamous cell carcinoma in a Chinese population. Int J Cancer. 2002;100:600–5.PubMedCrossRef

33.

Minelli C, Thompson JR, Abrams KR, Thakkinstian A, Attia J. How should we use information about HWE in the meta-analyses of genetic association studies? Int J Epidemiol. 2008;37:136–46.PubMedCrossRef

34.

Lunn RM, Helzlsouer KJ, Parshad R, Umbach DM, Harris EL, Sanford KK, et al. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis. 2000;21:551–5.PubMedCrossRef

35.

Au WW, Navasumrit P, Ruchirawat M. Use of biomarkers to characterize functions of polymorphic DNA repair genotypes. Int J Hyg Environ Health. 2004;107:301–13.CrossRef

36.

Vodicka P, Kumar R, Stetina R, Sanyal S, Soucek P, Haufroid V, et al. Genetic polymorphisms in DNA repair genes and possible links with DNA repair rates, chromosomal aberrations and single-strand breaks in DNA. Carcinogenesis. 2004;25:757–63.PubMedCrossRef

37.

Manuguerra M, Saletta F, Karagas MR, Berwick M, Veglia F, Vineis P, et al. XRCC3 and XPD/ERCC2 single nucleotide polymorphisms and the risk of cancer: a HuGE review. Am J Epidemiol. 2006;164:297–302.PubMedCrossRef

38.

Yuan L, Cui D, Zhao EJ, Jia CZ, Wang LD, Lu WQ. XPD Lys751Gln polymorphism and esophageal cancer risk: a meta-analysis involving 2288 cases and 4096 controls. World J Gastroenterol. 2011;17:2343–8.PubMedCentralPubMedCrossRef

Title: A pooled analysis of the ERCC2 Asp312Asn polymorphism and esophageal cancer susceptibility
Authors: Fang Wen
Zhiyong Zhao
Chuan Liu
Qinghua Yin
Jie Weng
Yajie Wang
Yuchen Ma
Publication date: 01-04-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 4/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-1380-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2014

Serum levels of macrophage migration-inhibitory factor (MIF) have diagnostic, predictive and prognostic roles in epithelial ovarian cancer patients

Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in patients with epithelial ovarian cancer

Proto-oncogene Wip1, a member of a new family of proliferative genes in NSCLC and its clinical significance

The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis

MDM2 rs2279744 polymorphism and endometrial cancer: a meta-analysis

Liver cancer-related gene CYP2E1 expression in HBV transgenic mice with acute liver injury

Keynote webinar | Spotlight on antibody–drug conjugates in cancer